Anthropic expands into drug discovery and readies $1 trillion IPO

Anthropic filed confidential paperwork to go public on June 1, targeting a possible $1 trillion valuation in a fall 2026 listing. The company reported annualized revenue approaching $50 billion and a Q2 run‑rate of $10.9 billion. Major shareholders include Amazon, which holds a mid‑to‑high‑teen percent stake valued at roughly $150 billion, and Alphabet, with about a 14‑15 percent stake worth $135 billion.

In parallel, Anthropic launched Claude Science, an AI‑driven research platform aimed at accelerating scientific work. The service bundles over 60 scientific databases and tools to support genomics, proteomics and other disciplines, and the firm announced an internal drug‑discovery programme focused on neglected diseases that are underserved by traditional pharma.

Anthropic also disclosed new interpretability research called the J‑Lens, revealing a self‑organised internal "J‑space" where Claude processes concepts before output. The team documented five functional properties of this workspace, positioning it as a potential compliance and audit tool for regulated industries.

Investors have shown strong interest: prediction‑market data favours Anthropic’s IPO over OpenAI, and token‑payment model scrutiny has prompted enterprise customers to consider cheaper alternatives, including Chinese open‑weight models.